# Ticagrelor

## Brilinta 90mg

##### 

| TAH Drug Code      | OBRI                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of atherothrombotic events in patients w/ acute coronary syndromes (ACS) [unstable angina, non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI)] including patients managed medically & managed w/ percutaneous coronary intervention (PCI) or CABG co-administered w/ acetylsalicylic acid (ASA). |
| Dosing             | Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis, needed an extended treatment: 60mg BID.                                                                                                      |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                    |
| Contraindications  | Active pathological bleeding, history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration w/ strong CYP3A4 inhibitors.                                                                                                                                                         |
| Adverse Effects    | Dyspnoea, epistaxis, GI haemorrhage, subcutaneous or dermal bleeding, bruising, procedural site haemorrhage.                                                                                                                                                                                                     |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                     |

